Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 9 December 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.

Under the programme initiated 11 November 2024, Novo Nordisk will repurchase B shares for an amount up to DKK 3,136,206,122.30 in the period from 11 November 2024 to 3 February 2025.

Since the announcement 2 December 2024, the following transactions have been made:

  Number of
B shares
Average
purchase price
Transaction
value, DKK
Accumulated, last announcement 1,224,005   905,425,967
2 December 2024 80,000 769.46 61,556,439
3 December 2024 74,974 784.58 58,822,855
4 December 2024 80,000 778.44 62,275,033
5 December 2024 78,000 769.13 59,992,220
6 December 2024 78,000 776.91 60,598,659
Accumulated under the programme 1,614,979   1,208,671,173

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 22,962,636 B shares of DKK 0.10 as treasury shares, corresponding to 0.5% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 20 billion during a 12-month period beginning 6 February 2024. As of 6 December 2024, Novo Nordisk has since 6 February 2024 repurchased a total 21,818,078 B shares at an average share price of DKK 828.33 per B share equal to a transaction value of DKK 18,072,465,051.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
                            


Contacts for further information

Media:  
Ambre James-Brown
+45 3079 9289
abmo@novonordisk.com

 
Liz Skrbkova (US)
+1 609 917 0632
lzsk@novonordisk.com

 
Investors:  
Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com

 
David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com

 
Sina Meyer
+45 3079 6656 azey@novonordisk.com

 
Ida Schaap Melvold
+45 3077 5649 idmg@novonordisk.com

 
Frederik Taylor Pitter
+1 609 613 0568
fptr@novonordisk.com

 
 


Company announcement No 94 / 2024

Attachments

  • CA20241209-share repurchase
  • CA20241209 safe harbour transaction details

Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Nov 2024 bis Dez 2024 Click Here for more Novo Nordisk Charts.
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Dez 2023 bis Dez 2024 Click Here for more Novo Nordisk Charts.